Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light

Vox Sanguinis

Volumn 107, Issue 4, 2014, Pages 351-359

  Bakkour, S ^a   Chafets, D M ^a   Wen, L ^a   van der Meer, P F ^b   Mundt, J M ^c   Marschner, S ^c   Goodrich, R P ^c   Busch, M P ^a   Lee, T H ^a  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b CENTRAL LABORATORY   (Netherlands)

^c Scientific and Clinical Affairs   (United States)

Author keywords

Mitochondrial DNA; Pathogen reduction; Plasma; Platelets; Quantitative PCR

Indexed keywords

MITOCHONDRIAL DNA; RIBOFLAVIN;

AMPLICON; APHERESIS; ARTICLE; CONTROLLED STUDY; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MEASUREMENT ACCURACY; PREDICTION; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; THROMBOCYTE COUNT; ULTRAVIOLET RADIATION; BLOODBORNE BACTERIUM; DRUG EFFECTS; GENETICS; METABOLISM; MICROBIOLOGY; MITOCHONDRION; PLASMA; RADIATION RESPONSE; STANDARDS; THROMBOCYTE;

BLOOD PLATELETS; BLOOD-BORNE PATHOGENS; DNA, MITOCHONDRIAL; HUMANS; MITOCHONDRIA; PLASMA; QUALITY CONTROL; REAL-TIME POLYMERASE CHAIN REACTION; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 84912012609     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12173     Document Type: Article

References (24)

1. Stramer SL, Dodd RY, AABB Transfusion-Transmitted Diseases Emerging Infectious Diseases Subgroup: Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion 2013; 53:2375-2383
2. Prowse CV: Component pathogen inactivation: a critical review. Vox Sang 2013; 104:183-199
3. Marschner S, Goodrich R: Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011; 38:8-18
4. Kumar V, Lockerbie O, Keil SD, et al.: Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80:15-21
5. Ruane PH, Edrich R, Gampp D, et al.: Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877-885
6. Cardo LJ, Salata J, Mendez J, et al.: Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 37:131-137
7. Goodrich RP, Gilmour D, Hovenga N, et al.: A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49:1205-1216
8. Keil SD, Kiser P, Sullivan JJ, et al.: Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion 2013; 53:2278-2286
9. Vanlandingham DL, Keil SD, Horne KM, et al.: Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013; 53:284-290
10. AuBuchon JP, Herschel L, Roger J, et al.: Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45:1335-1341
11. Picker SM, Steisel A, Gathof BS: Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008; 48:1685-1692
12. Hornsey VS, Drummond O, Morrison A, et al.: Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009; 49:2167-2172
13. Cazenave JP, Folléa G, Bardiaux L, et al.: A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50:2362-2375
14. Smith J, Rock G: Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion 2010; 50:926-931
15. Johansson PI, Simonsen AC, Brown PN, et al.: A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia. Transfusion 2013; 53:2043-2052
16. Allain JP, Hsu J, Pranmeth M, et al.: Quantification of viral inactivation by photochemical treatment with amotosalen and UV A light, using a novel polymerase chain reaction inhibition method with preamplification. J Infect Dis 2006; 194:1737-1744
17. El Chaar M, Atwal S, Freimanis GL, et al.: Inactivation of Plasmodium falciparum in whole blood by riboflavin plus irradiation. Transfusion 2013; 53:3174-3183
18. Bruchmuller I, Janetzko K, Bugert P, et al.: Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates. Transfusion 2005; 45:1464-1472
19. Lauring AS, Lee TH, Martin JN, et al.: Lack of evidence for mtDNA as a biomarker of innate immune activation in HIV infection. PLoS ONE 2012; 7:e50486
20. Levin BC, Cheng H, Reeder DJ: A human mitochondrial DNA standard reference material for quality control in forensic identification, medical diagnosis, and mutation detection. Genomics 1999; 55:135-146
21. Martin CB, Wilfong E, Ruane P, et al.: An action spectrum of the riboflavin-photosensitized inactivation of Lambda phage. Photochem Photobiol 2005; 81:474-480
22. Sikorsky JA, Primerano DA, Fenger TW, et al.: Effect of DNA damage on PCR amplification efficiency with the relative threshold cycle method. Biochem Biophys Res Commun 2004; 323:823-830
23. Council of Europe, European Directorate for the Quality of Medicines & Healthcare, European Committee on Blood Transfusion (CD-P-TS): Guide to the preparation, use and quality assurance of blood components, 17th edition [Internet]. Strasbourg (France), 2013 [cited 2013 Sep 30]. p124. Available from: www.edqm.eu/en/blood-transfusion-guides-1608.html ISBN: 978-92-871-7637-0
24. Osman A, Hitzler WE, Meyer CU, et al.: Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets 2014; doi:10.3109/09537104.2014.898178 (Epub ahead of print)